Atlas Trials

A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

Clinical trial NCT05263869 · UNKNOWN

Trial details

NCT number
NCT05263869
Sponsor
Shanghai Miracogen Inc.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer With Liver Metastases
Start date
2022-03-23
Primary completion
2022-12-01
Enrollment
99

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.